Breast cancer has become the most prevalent cancer type in the world. The classic PAM50 classification provides guidance for the selection of clinical treatment strategies and suggests the huge individual differences in breast cancer. The emergence of immune checkpoint inhibitors has made a breakthrough in breast cancer management. Nevertheless, the application of immunotherapy is also limited by the large heterogeneity between individual and molecular types. This interindividual variation focuses on the heterogeneity of the body's immunity caused by the complex tumor immune microenvironment (TIM). The TIM has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and clinical management, as well as multifaceted mechanisms of tumor progression. TIM is concerned to be the key factor to determine the benefit of immunotherapy, but the complex breast cancer immune microenvironment lacks in-depth and systematic characterization. Therefore, strengthening the understanding of the breast cancer immune microenvironment is not only the key to analyzing the immune regulation mechanism but also has guiding significance for improving the clinical efficacy of immunotherapy.
This topic focuses on the delineation of the TIM molecular map of breast cancer and the multi-omics study of specific molecular regulatory mechanisms, so as to elucidate the characteristics of the breast cancer immune microenvironment, explore its specific properties, relationships, and dynamic changes, and help identify the biomarkers of immunotherapy.
Researchers are invited to contribute to the manuscript of hominid studies and reviews to elucidate the topic of effective interventions targeting molecular mechanisms of the immune microenvironment for breast cancer. We welcome original articles, comments, and opinions on subtopics of interest, including but not limited to subtopics:
•Using transcriptome and genomics to identify novel biomarkers in the breast cancer immune microenvironment.
•Innovation and application of advanced sequencing technology in the study of TIM regulatory mechanism of breast cancer: single-cell sequencing, spatial transcriptome sequencing, antigen receptor sequencing, etc.
•Identifying TIM subtypes of breast cancer and analyzing their characteristics.
•Assessing temporal and spatial heterogeneity of the TIM and clinical guidance of immunotherapy based on different molecular subtypes.
Please note that bioinformatic papers need a combination data analysis and for totally no less than 3 additional validation datasets or 500 patient cases. The focus will be on papers linking genotype-phenotype relationships; However, papers will be considered case by case based on overall merit.
Breast cancer has become the most prevalent cancer type in the world. The classic PAM50 classification provides guidance for the selection of clinical treatment strategies and suggests the huge individual differences in breast cancer. The emergence of immune checkpoint inhibitors has made a breakthrough in breast cancer management. Nevertheless, the application of immunotherapy is also limited by the large heterogeneity between individual and molecular types. This interindividual variation focuses on the heterogeneity of the body's immunity caused by the complex tumor immune microenvironment (TIM). The TIM has become a recent research hot spot, providing novel but valuable insight into tumor heterogeneity and clinical management, as well as multifaceted mechanisms of tumor progression. TIM is concerned to be the key factor to determine the benefit of immunotherapy, but the complex breast cancer immune microenvironment lacks in-depth and systematic characterization. Therefore, strengthening the understanding of the breast cancer immune microenvironment is not only the key to analyzing the immune regulation mechanism but also has guiding significance for improving the clinical efficacy of immunotherapy.
This topic focuses on the delineation of the TIM molecular map of breast cancer and the multi-omics study of specific molecular regulatory mechanisms, so as to elucidate the characteristics of the breast cancer immune microenvironment, explore its specific properties, relationships, and dynamic changes, and help identify the biomarkers of immunotherapy.
Researchers are invited to contribute to the manuscript of hominid studies and reviews to elucidate the topic of effective interventions targeting molecular mechanisms of the immune microenvironment for breast cancer. We welcome original articles, comments, and opinions on subtopics of interest, including but not limited to subtopics:
•Using transcriptome and genomics to identify novel biomarkers in the breast cancer immune microenvironment.
•Innovation and application of advanced sequencing technology in the study of TIM regulatory mechanism of breast cancer: single-cell sequencing, spatial transcriptome sequencing, antigen receptor sequencing, etc.
•Identifying TIM subtypes of breast cancer and analyzing their characteristics.
•Assessing temporal and spatial heterogeneity of the TIM and clinical guidance of immunotherapy based on different molecular subtypes.
Please note that bioinformatic papers need a combination data analysis and for totally no less than 3 additional validation datasets or 500 patient cases. The focus will be on papers linking genotype-phenotype relationships; However, papers will be considered case by case based on overall merit.
